{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:05:15Z","timestamp":1784613915837,"version":"3.55.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Sexual dysfunction is a common and clinically significant problem in patients treated with antidepressants and antipsychotics, yet it remains under-recognized in routine psychiatric practice. Its relevance extends beyond tolerability, as it may adversely affect quality of life, intimate relationships, self-esteem, and long-term adherence. A major clinical and methodological challenge is that sexual dysfunction frequently precedes pharmacotherapy, particularly in depressive and psychotic disorders, making it essential to distinguish illness-related impairment from treatment-emergent dysfunction. This narrative review provides an integrated overview of sexual dysfunction associated with antidepressants and antipsychotics, with emphasis on mechanisms, clinical assessment, and management. We summarize current evidence on the comparative risk across major drug classes and selected individual agents, highlighting the generally higher burden associated with strongly serotonergic antidepressants and prolactin-elevating antipsychotics, as well as the relatively more favorable profiles of selected newer or prolactin-sparing compounds. We further examine the principal serotonergic, dopaminergic, endocrine, autonomic, and vascular mechanisms involved, and discuss their relevance to the different domains of sexual functioning. Finally, we review practical strategies for routine care, including baseline evaluation, direct questioning, validated rating instruments, prevention through drug selection, dose adjustment, switching, and adjunctive interventions. Sexual dysfunction should be regarded as a meaningful clinical outcome in psychopharmacology, and its systematic assessment should be incorporated into routine treatment planning and follow-up.<\/jats:p>","DOI":"10.3389\/fpsyt.2026.1865752","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:35:51Z","timestamp":1784612151000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sexual dysfunction associated with antidepressants and antipsychotics: a structured narrative review of mechanisms, assessment, and personalized management"],"prefix":"10.3389","volume":"17","author":[{"given":"Djendji","family":"Siladji","sequence":"first","affiliation":[{"name":"Clinic for Psychiatry, University Clinical Center of Vojvodina","place":["Novi Sad, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nemanja","family":"Maletin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad","place":["Novi Sad, Serbia"]},{"name":"Clinic of Internal Oncology, Oncology Institute of Vojvodina","place":["Sremska Kamenica, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Denda","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad","place":["Novi Sad, Serbia"]},{"name":"Clinic for Eye Diseases, University Clinical Center of Vojvodina","place":["Novi Sad, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Kne\u017eevi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad","place":["Novi Sad, Serbia"]},{"name":"Clinic for Gastroenterology and Hepatology, University Clinical Center of Vojvodina","place":["Novi Sad, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Paut Kusturica","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad","place":["Novi Sad, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du\u0161an","family":"Kuljan\u010di\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Psychiatry, University Clinical Center of Vojvodina","place":["Novi Sad, Serbia"]},{"name":"Faculty of Medicine, University of Novi Sad","place":["Novi Sad, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Ra\u0161kovi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad","place":["Novi Sad, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2049753","article-title":"Sexual dysfunction with major depressive disorder and antidepressant treatments: impact, assessment, and management","volume":"21","author":"Winter","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.951324","article-title":"Sexual dysfunction associated with major depressive disorder and antidepressant treatment","volume":"13","author":"Clayton","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/wps.20509","article-title":"The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management","volume":"17","author":"Montejo","year":"2018","journal-title":"World Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2016.04.006","article-title":"Sexual dysfunction due to psychotropic medications","volume":"39","author":"Clayton","year":"2016","journal-title":"Psychiatr Clin North Am"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8101640","article-title":"Management strategies for antidepressant-related sexual dysfunction: a clinical approach","volume":"8","author":"Montejo","year":"2019","journal-title":"J Clin Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10020308","article-title":"Management strategies for antipsychotic-related sexual dysfunction: a clinical approach","volume":"10","author":"Montejo","year":"2021","journal-title":"J Clin Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2012.02709.x","article-title":"Bidirectional association between depression and sexual dysfunction: a systematic review and meta-analysis","volume":"9","author":"Atlantis","year":"2012","journal-title":"J Sex Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41443-022-00539-7","article-title":"Prevalence of sexual dysfunction in depressive and persistent depressive disorders: a systematic review and meta-analysis","volume":"35","author":"Goncalves","year":"2023","journal-title":"Int J Impot Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(99)00050-6","article-title":"Sexual dysfunction before antidepressant therapy in major depression","volume":"56","author":"Kennedy","year":"1999","journal-title":"J Affect Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.111.101220","article-title":"Sexual dysfunction in people with prodromal or first-episode psychosis","volume":"201","author":"Marques","year":"2012","journal-title":"Br J Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.06.004","article-title":"Sexual dysfunction in Chinese patients with first-episode psychosis: prevalence, clinical correlates and functioning","volume":"148","author":"Hui","year":"2013","journal-title":"Schizophr Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181a5233f","article-title":"Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis","volume":"29","author":"Serretti","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13643-021-01671-z","article-title":"How to properly use the PRISMA Statement","volume":"10","author":"Sarkis-Onofre","year":"2021","journal-title":"Systematic Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s00228-026-04011-z","article-title":"Sexual dysfunction associated with selective serotonin reuptake inhibitors in adults with depression: a systematic review and meta-analysis","volume":"82","author":"Dagostin Ferraz","year":"2026","journal-title":"Eur J Clin Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12888-025-06751-1","article-title":"Antidepressant-associated sexual dysfunction in outpatients","volume":"25","author":"Safak","year":"2025","journal-title":"BMC Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000094","article-title":"Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysis","volume":"30","author":"Clayton","year":"2015","journal-title":"Int Clin Psychopharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2012.02899.x","article-title":"An evaluation of sexual functioning in employed outpatients with major depressive disorder treated with desvenlafaxine 50 mg or placebo","volume":"10","author":"Clayton","year":"2013","journal-title":"J Sex Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/jsm.12980","article-title":"Effect of vortioxetine vs escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-induced sexual dysfunction","volume":"12","author":"Jacobsen","year":"2015","journal-title":"J Sex Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000075","article-title":"Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial","volume":"30","author":"Clayton","year":"2015","journal-title":"Int Clin Psychopharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1115008","article-title":"Agomelatine in the treatment of anhedonia, somatic symptoms, and sexual dysfunction in major depressive disorder","volume":"14","author":"Huang","year":"2023","journal-title":"Front Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1243","article-title":"The effects of agomelatine on sexual function in depressed patients and healthy volunteers","volume":"26","author":"Montejo","year":"2011","journal-title":"Hum Psychopharmacol - Clin Exp"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.90170","article-title":"Management of antidepressant-induced sexual dysfunction: a literature review","volume":"17","author":"Tran","year":"2025","journal-title":"Cureus"},{"key":"B24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.5005\/jp-journals-10067-0143","article-title":"Sexual dysfunction with antidepressants: a clinical review","volume":"17","author":"Motwani","year":"2023","journal-title":"Indian J Private Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1017\/S1092852921000377","article-title":"Pharmacologic interventions for antidepressant-induced sexual dysfunction: a systematic review and network meta-analysis of trials using the Arizona sexual experience scale","volume":"27","author":"Luft","year":"2022","journal-title":"CNS Spectrums"},{"key":"B26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.17712\/nsj.2020.1.20190058","article-title":"Prevalence of antidepressant-induced sexual dysfunction among psychiatric outpatients attending a tertiary care hospital","volume":"25","author":"AlBreiki","year":"2020","journal-title":"Neurosci J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.5534\/wjmh.2012.30.3.153","article-title":"Antipsychotic-induced sexual dysfunction and its management","volume":"30","author":"Park","year":"2012","journal-title":"World J Mens Health"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.2696","article-title":"Sexual dysfunction in schizophrenia: a systematic review and meta-analysis","volume":"80","author":"Korchia","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001297","article-title":"Effect of brexpiprazole on prolactin and sexual functioning: an analysis of short-and long-term study data in major depressive disorder","volume":"40","author":"Clayton","year":"2020","journal-title":"J Clin Psychopharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000979","article-title":"Effect of brexpiprazole on prolactin: an analysis of short-and long-term studies in schizophrenia","volume":"39","author":"Ivkovic","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15093320","article-title":"Improvement in antipsychotic-related sexual dysfunction after switching to cariprazine: a prospective real-world study","volume":"15","author":"Montejo","year":"2026","journal-title":"J Clin Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-025-00620-7","article-title":"Managing schizophrenia with affective, sexual, metabolic and substance-use comorbidities: pharmacological considerations from an expert consensus","volume":"25","author":"Vieta","year":"2026","journal-title":"Ann Gen Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.18m12132","article-title":"Effect of lurasidone on sexual function in major depressive disorder patients with subthreshold hypomanic symptoms (mixed features): results from a placebo-controlled trial","volume":"79","author":"Clayton","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S0924-9338(15)32095-2","article-title":"Lurasidone and sexual dysfunction: post-hoc analysis of pooled data","volume":"30","author":"dos Reis","year":"2015","journal-title":"Eur Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1423075","article-title":"The atypical antipsychotics and sexual dysfunction: a pharmacovigilance-pharmacodynamic study","volume":"15","author":"Cheng","year":"2024","journal-title":"Front Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-6163.2002.tb00665.x","article-title":"Mechanisms and treatments of SSRI-induced sexual dysfunction","volume":"38","author":"Keltner","year":"2002","journal-title":"Perspect Psychiatr Care"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinsp.2025.100602","article-title":"Pharmacological treatment of antidepressant-induced sexual dysfunction in women: a systematic review and meta-analysis of randomized clinical trials","volume":"80","author":"de Aquino","year":"2025","journal-title":"Clinics"},{"key":"B38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/009262300278623","article-title":"The Arizona Sexual Experience Scale (ASEX): reliability and validity","volume":"26","author":"McGahuey","year":"2000","journal-title":"J Sex Marital Ther"},{"key":"B39","doi-asserted-by":"crossref","DOI":"10.54915\/gnav2983","article-title":"The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity","volume":"33","author":"Clayton","year":"1997","journal-title":"Psychopharmacol Bull"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/00926230701866125","article-title":"Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders","volume":"34","author":"Montejo","year":"2008","journal-title":"J Sex Marital Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2011.05.022","article-title":"Psychometric evaluation of the antipsychotics and sexual functioning questionnaire (ASFQ)","volume":"131","author":"Garc\u00eda-Portilla","year":"2011","journal-title":"Schizophr Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50522","article-title":"Antidepressant-induced sexual dysfunction","volume":"212","author":"Rothmore","year":"2020","journal-title":"Med J Aust"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/ph17070826","article-title":"Sexual dysfunction induced by antidepressants: a pharmacovigilance study using data from VigiBase","volume":"17","author":"Zeiss","year":"2024","journal-title":"Pharm (Basel)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796024000441","article-title":"Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence","volume":"33","author":"Healy","year":"2024","journal-title":"Epidemiol Psychiatr Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1192\/bjpo.bp.115.001248","article-title":"Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial","volume":"1","author":"Raghuthaman","year":"2015","journal-title":"BJPsych Open"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.encep.2023.11.025","article-title":"Management strategies for antidepressant-related sexual dysfunction","volume":"50","author":"Lach","year":"2024","journal-title":"L'encephale"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000898","article-title":"Adjunct aripiprazole reduces prolactin and prolactin-related adverse effects in premenopausal women with psychosis: results from the DAAMSEL clinical trial","volume":"38","author":"Kelly","year":"2018","journal-title":"J Clin Psychopharmacol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00812-1","article-title":"Is adjunct aripiprazole effective in treating hyperprolactinemia induced by psychotropic medication? A narrative review","volume":"35","author":"Besag","year":"2021","journal-title":"CNS Drugs"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1337274","article-title":"Treatment of antipsychotic-induced hyperprolactinemia: an umbrella review of systematic reviews and meta-analyses","volume":"15","author":"Jiang","year":"2024","journal-title":"Front Psychiatry"},{"key":"B50","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41398-022-02027-4","article-title":"Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis","volume":"12","author":"Lu","year":"2022","journal-title":"Transl Psychiatry"},{"key":"B51","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.sxmr.2017.07.002","article-title":"Post-SSRI sexual dysfunction: a literature review","volume":"6","author":"Bala","year":"2018","journal-title":"Sex Med Rev"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m754","article-title":"Post-SSRI sexual dysfunction","volume":"368","author":"Reisman","year":"2020","journal-title":"BMJ"},{"key":"B53","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3233\/JRS-210023","article-title":"Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin","volume":"33","author":"Healy","year":"2022","journal-title":"Int J Risk Saf Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2009.4","article-title":"Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients","volume":"34","author":"Perlis","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1006","article-title":"The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)\u2010associated sexual side effects: possible relationship to oral contraceptives","volume":"24","author":"Bishop","year":"2009","journal-title":"Hum Psychopharmacol - Clin Exp"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.14.114","article-title":"Genetic determinants of selective serotonin reuptake inhibitor related sexual dysfunction","volume":"15","author":"Stevenson","year":"2014","journal-title":"Pharmacogenomics"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1865752\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:35:52Z","timestamp":1784612152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1865752\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":56,"alternative-id":["10.3389\/fpsyt.2026.1865752"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1865752","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"1865752"}}